Speaker
Description
Jumjar Taipodia1*, Chiging Sonia2, Tado Karlo3
123Department of Physics, NERIST-791109, Arunachal Pradesh, India
Email: jumjart@gmail.com
ABSTRACT
Atopic dermatitis (AD) is a chronic inflammatory skin disorder characterized by epidermal barrier dysfunction, immune dysregulation, and persistent pruritus. Dysregulation of the Janus kinase/signal transducer and activator of transcription (JAK/STAT) pathway contributes to inflammatory signalling in AD. Tofacitinib is a Janus kinase inhibitor with activity against JAK1 and JAK3 and has shown therapeutic potential in inflammatory skin disorders. Pyridoxine (vitamin B6) has attracted interest due to its reported effects on filaggrin production and inflammatory responses in experimental studies. The present study focuses on understanding the structural, geometrical, electronic, pharmacokinetic, and interaction properties of tofacitinib-pyridoxine complex using computational approaches. The molecular geometries of tofacitinib, pyridoxine, and their complex are optimized using the Density Functional Theory (DFT) approach at the B3LYP/6-311++G(d,p) level of theory using Gaussian 09W software. Frontier molecular orbitals, molecular electrostatic potential (MEP), natural bond orbital (NBO) analysis, and global reactivity descriptors are evaluated to investigate the electronic properties, reactivity, and stability of the molecules. Atoms in Molecules (AIM) analysis is performed to examine electron density and bond critical points associated with the intermolecular interactions. Drug-likeness, physicochemical properties, and pharmacokinetic characteristics are evaluated using the SwissADME tool. Molecular docking simulations are performed using AutoDock 4.0 against selected protein targets associated with AD to investigate binding poses, docking scores, and key ligand-target interactions. The results provide computational insights into the structural, electronic, and pharmacokinetic properties of tofacitinib-pyridoxine complex, providing a theoretical basis for further experimental investigation.
Keywords: Tofacitinib; Pyridoxine; DFT; Molecular Docking